Arasena-A en es it fr

Arasena-A Brand names, Arasena-A Analogs

Arasena-A Brand Names Mixture

  • No information avaliable

Arasena-A Chemical_Formula


Arasena-A RX_link

Arasena-A fda sheet

Arasena-A msds (material safety sheet)

Arasena-A Synthesis Reference

No information avaliable

Arasena-A Molecular Weight

285.257 g/mol

Arasena-A Melting Point

No information avaliable

Arasena-A H2O Solubility

No information avaliable

Arasena-A State


Arasena-A LogP


Arasena-A Dosage Forms

No information avaliable

Arasena-A Indication

For treatment of chickenpox - varicella, herpes zoster and herpes simplex

Arasena-A Pharmacology

Vidarabine is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV). The inhibitory activity of Vidarabine is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts Vidarabine into Vidarabine monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. in vitro, Vidarabine triphosphate stops replication of herpes viral DNA. When used as a substrate for viral DNA polymerase, Vidarabine triphosphate competitively inhibits dATP leading to the formation of 'faulty' DNA. This is where Vidarabine triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand.

Arasena-A Absorption

No information avaliable

Arasena-A side effects and Toxicity

No information avaliable

Arasena-A Patient Information

No information avaliable

Arasena-A Organisms Affected

Human Herpes Viruses